Adarsh Chaudhary1, J Enrique Domínguez-Muñoz2, Peter Layer3, Markus M Lerch4. 1. Department of Gastrointestinal Surgery, Gastrointestinal Oncology and Bariatric Surgery, Medanta, The Medicity, Gurgaon, India, adarsh_chaudhary@yahoo.com. 2. Department of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain. 3. Department of Medicine, Israelitic Hospital, University of Hamburg, Hamburg, Germany. 4. Department of Medicine, University Medicine Greifswald, Greifswald, Germany.
Abstract
BACKGROUND: Pancreatic exocrine insufficiency (PEI) is characterized by inadequate production, insufficient secretion, and/or inactivation of pancreatic enzymes, resulting in maldigestion. The aim of this review was to analyze the prevalence and pathophysiology of PEI resulting from gastrointestinal (GI) surgery and to examine the use of pancreatic enzyme replacement therapy (PERT) for effectively managing PEI. SUMMARY: A targeted PubMed search was conducted for studies examining the prevalence and pathophysiology of PEI in patients following GI surgery and for studies assessing the effects of PERT in these patients. PEI is a common complication following GI surgery that can lead to nutritional deficiencies, which may contribute to morbidity and mortality in patients. Timely treatment of PEI with PERT can prevent malnutrition, increase quality of life, and possibly reduce the associated mortality. Treatment of PEI should aim not only to alleviate symptoms but also to achieve significant improvements in nutritional parameters. Dose optimization of PERT is required for effective management of PEI, in addition to regular assessment of nutritional status, appropriate patient education, and reassessment if symptoms return. Key Messages: Difficulties in detecting PEI following GI surgery can result in undiagnosed and untreated maldigestion, leading to metabolic complications and increased morbidity. Both are preventable by early administration and monitoring for optimal doses of PERT. The Author(s). Published by S. Karger AG, Basel.
BACKGROUND:Pancreatic exocrine insufficiency (PEI) is characterized by inadequate production, insufficient secretion, and/or inactivation of pancreatic enzymes, resulting in maldigestion. The aim of this review was to analyze the prevalence and pathophysiology of PEI resulting from gastrointestinal (GI) surgery and to examine the use of pancreatic enzyme replacement therapy (PERT) for effectively managing PEI. SUMMARY: A targeted PubMed search was conducted for studies examining the prevalence and pathophysiology of PEI in patients following GI surgery and for studies assessing the effects of PERT in these patients. PEI is a common complication following GI surgery that can lead to nutritional deficiencies, which may contribute to morbidity and mortality in patients. Timely treatment of PEI with PERT can prevent malnutrition, increase quality of life, and possibly reduce the associated mortality. Treatment of PEI should aim not only to alleviate symptoms but also to achieve significant improvements in nutritional parameters. Dose optimization of PERT is required for effective management of PEI, in addition to regular assessment of nutritional status, appropriate patient education, and reassessment if symptoms return. Key Messages: Difficulties in detecting PEI following GI surgery can result in undiagnosed and untreated maldigestion, leading to metabolic complications and increased morbidity. Both are preventable by early administration and monitoring for optimal doses of PERT. The Author(s). Published by S. Karger AG, Basel.
Authors: Markus Winny; Vagia Paroglou; Hüseyin Bektas; Alexander Kaltenborn; Benedikt Reichert; Lea Zachau; Moritz Kleine; Jürgen Klempnauer; Harald Schrem Journal: Surgery Date: 2013-11-25 Impact factor: 3.982
Authors: Bronwen Rhodes; Edward F Nash; Elizabeth Tullis; Paul B Pencharz; Michelle Brotherwood; Annie Dupuis; Anne Stephenson Journal: J Cyst Fibros Date: 2009-10-29 Impact factor: 5.482
Authors: H Friess; J Böhm; M W Müller; B Glasbrenner; R L Riepl; P Malfertheiner; M W Büchler Journal: Am J Gastroenterol Date: 1996-02 Impact factor: 10.864
Authors: Edmée C M Sikkens; Djuna L Cahen; Casper van Eijck; Ernst J Kuipers; Marco J Bruno Journal: J Gastrointest Surg Date: 2012-06-19 Impact factor: 3.452
Authors: Lumír Kunovský; Petr Dítě; Petr Jabandžiev; Michal Eid; Karolina Poredská; Jitka Vaculová; Dana Sochorová; Pavel Janeček; Pavla Tesaříková; Martin Blaho; Jan Trna; Jan Hlavsa; Zdeněk Kala Journal: J Clin Med Date: 2021-12-10 Impact factor: 4.241